Core Viewpoint - Scorpius Holdings, Inc. has launched Scorpius Ventures, a new business unit aimed at supporting emerging biotech companies through a flexible American onshoring model, combining service fees with equity stakes to lower financial barriers for onshoring production of biologics [1][3][5] Group 1: Business Model and Strategy - Scorpius Ventures employs a hybrid model that provides capital-efficient access to cGMP manufacturing services via in-kind equity investment, allowing clients to share in growth potential [2] - The new venture aligns with the BIOSECURE Act, promoting onshore production of essential biological substances to enhance national security and economic resilience [3][5] - By prioritizing U.S.-based manufacturing, Scorpius Ventures aims to improve supply chain stability and foster domestic job growth [3] Group 2: Benefits to Partners - Biotech partners can leverage Scorpius' industry-leading CMC and manufacturing expertise, which ensures streamlined development, reduced risks, and clear communication regarding milestones and timelines [4] - The combination of operational support with a fee-and-equity model enables clients to utilize the company's manufacturing strengths to assist in their fundraising efforts [4] Group 3: Company Overview - Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on advancing biologic programs, offering a wide range of analytical testing, process development, and manufacturing services at its facilities in San Antonio, TX [6]
Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model